Saving lives with Narcan is only the first step; systemic support must follow
While naloxone can reverse an overdose, gaps in Medicaid, funding and post-incarceration care threaten long-term survival.
Naloxone saves lives in the moment of an overdose, but the real challenge lies in ensuring that survivors receive timely treatment and ongoing support. Delays in Medicaid approval, unstable federal grant financing, and interruptions caused by jail bookings leave many at risk of another fatal episode. Although overdose deaths fell sharply in 2024 and appear to be declining in 2025, only a small portion of the 47.2 million people who need substance-use treatment actually obtain it, and merely 16 % of those with opioid use disorder receive medication.
The House FY 2027 appropriations plan keeps major state treatment grants steady but cuts funding for harm-reduction initiatives like naloxone distribution. Legislative options such as the Due Process Continuity of Care Act and an updated PEER Support Act could protect Medicaid coverage during pre-trial detention and bolster the peer-support workforce. The piece warns that interpreting the recent mortality drop as a sign the crisis is solved would be premature; sustained, coordinated funding is required to keep the gains alive.
Why it matters
Without continuous treatment and funding, people who survive an overdose remain vulnerable to death, undermining public-health gains.
In this story
